Research Topics
| Ola E DahlSummaryAffiliation: University of Oslo Country: Norway Publications
| Collaborators
|
Detail Information
Publications
Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgeryOla E Dahl
Department of Orthopaedics and Research Forum, Ullevaal University Hospital, Oslo, Norway
Curr Opin Pulm Med 8:394-7. 2002..Clinical studies on vascular endpoints are warranted to achieve relevant basic data for health economic analyses, which also lack scientific standardized procedures. An intercontinental close cooperation is needed to solve these issues...- Fatal vascular outcomes following major orthopedic surgeryOla E Dahl
Thrombosis Research Institute, London, UK
Thromb Haemost 93:860-6. 2005..In conclusion, although prophylaxis results in a reduction in overall mortality and fatal pulmonary embolism, vascular events continue to be a common cause of mortality... - Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialBengt I Eriksson
Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
Lancet 370:949-56. 2007..After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis... 
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialAjay K Kakkar
Barts and the London School of Medicine and Dentistry, London, UK
Lancet 372:31-9. 2008..Our aim was to compare the use of rivaroxaban for extended thromboprophylaxis with short-term thromboprophylaxis with enoxaparin...
What treatment for periprosthetic shoulderinfection? Results from a multicentre retrospective seriesCarlo Luca Romano
Dipartimento di Chirurgia Ricostruttiva e delle InfezioniOsteo articolari, Istituto Ortopedico I R C C S Galeazzi, Via Riccardo Galeazzi, 4, Milano 20161, Italy
Int Orthop 36:1011-7. 2012..The aim of this multi-institutional study was to review a continuous retrospectiveseries of patients treated in four European centres and to assess the respective eradication rate of various treatment approaches...- Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]Ola E Dahl
Department of Orthopaedics, Elverum Central Hospital, Kirkevn 7, 2418 Elverum, Norway
Int Orthop 36:741-8. 2012..Our objective was to understand the efficacy and bleeding data for the lower dose in this subpopulation... - New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disordersOla E Dahl
Department of Orthopaedics, Innlandet Hospital Trust, Elverum Central Hospital, Elverum, Norway
Vasc Health Risk Manag 8:45-57. 2012.... - Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3,954 patientsOla E Dahl
Department of Orthopaedics and Research Forum, Ulleval University Hospital, Oslo, Norway
Acta Orthop Scand 74:299-304. 2003..The differences in PE incidence and the time when it developed in NHF versus THR and TKR patients suggest that these patients should be considered separately when determining the optimal thromboprophylactic regimen... - Orthopaedic surgery as a model for drug development in thrombosisOla E Dahl
Department of Orthopaedics, Buskerud Central Hospital, Section for Joint Implants and Medical Science, Drammen, Norway
Drugs 64:17-25. 2004..In addition, geographical differences in treatment regimens regarding the choice of agent, timing of initiation and duration of thromboprophylaxis, and how these influence the incidence of venous thromboembolism, will be discussed... - Divergent regional opinions on thromboembolic complications and prophylaxis among surgeonsO E Dahl
Thrombosis Research Institute, London, UK
J Thromb Haemost 2:1899-900. 2004 - Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimenOla E Dahl
Department of Orthopaedics, Elverum Central Hospital, Norway, and Thrombosis Research Institute, London, United Kingdom
Clin Appl Thromb Hemost 15:17S-24S. 2009..These doses were selected to ensure that the risk of bleeding did not exceed that of enoxaparin. This review discusses the rationale for selection of these dose regimens based on results from phase II trials... - Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical useO E Dahl
International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK
Int Angiol 27:60-7. 2008..In this paper, the International Surgical Thrombosis Forum proposes a strategy for the clinical investigation of new pharmacological agents for the prophylaxis of postoperative thrombotic events... - Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplastyOla E Dahl
International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK
Pathophysiol Haemost Thromb 35:428-34. 2006..4-12 h) when compared with preoperative (12 h) administration of enoxaparin. Transfusion rates were significantly lower with administration of melagatran/ximelagatran compared with enoxaparin... - Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacementO E Dahl
Department of Orthopaedics, Research Forum, Ullevaal University Hospital, Oslo, Norway
J Thromb Haemost 1:896-906. 2003..We consider that investment in prolonged thromboprophylaxis with dalteparin is justified for the improvement in clinical outcomes produced... - Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now?O E Dahl
Department of Orthopaedics, Ullevaal University Hospital, Oslo, Norway
Haemostasis 30:101-5; discussion 82-3. 2000.... - Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THAPål O Borgen
Department of Orthopaedics, Martina Hansens Hospital, Oslo, Norway
Hip Int 20:301-7. 2010..Few thromboembolic events occurred, and these were equally distributed... - Ximelagatran as a new oral anticoagulant for thrombosisOla E Dahl
Thrombosis Research Institute, London, United Kingdom
Semin Vasc Med 5:223-5. 2005 - Biochemical lung, liver and kidney markers and early death among elderly following hip fractureOve Talsnes
Department of Orthopaedics, Sykehuset Innlandet Hospital Trust, Elverum, Norway
Arch Orthop Trauma Surg 132:1753-8. 2012..This study was conducted to assess biological markers on perioperative organ dysfunction and its association with early mortality within 3 months after surgery... - Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparinH Arnesen
Center for Clinical Research, Department of Orthopedic Surgery, Ulleval University Hospital, Oslo, Norway
J Thromb Haemost 1:971-5. 2003..0 when compared with patients in the lowest quartile (<1625 ng mL-1). It is concluded that a substantial hypercoagulability is sustained until day 35 after HRS, significantly reduced with prolonged administration of dalteparin... - Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgeryD J Quinlan
Department of Radiology, King s College Hospital, London, UK
J Thromb Haemost 5:1438-43. 2007..Venography is commonly used to compare the efficacy of different thromboprophylaxis strategies for preventing deep vein thrombosis (DVT) in patients undergoing total hip replacement (THR) or total knee replacement (TKR)... - Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)O E Dahl
Department of Orthopaedics, Ullevaal University Hospital, Oslo, Norway
Thromb Haemost 77:26-31. 1997..This study shows that prolonged thromboprophylaxis with dalteparin. 5000 IU, once daily for 35 days significantly reduces the frequency of DVT and should be recommended for 5 weeks after hip replacement surgery... - Thromboprophylaxis in hip arthroplasty. New frontiers and future strategyO E Dahl
Department of Orthopaedics, Ullevaal University Hospital, Oslo, Norway
Acta Orthop Scand 69:339-42. 1998..Prolonged thrombo-prophylaxis with low-molecular-weight heparin (dalteparin or enoxaparin) is recommended for at least 5 weeks after the operation... - Clinical and biochemical prediction of early fatal outcome following hip fracture in the elderlyOve Talsnes
Department of Orthopaedics, Elverum Central Hospital, Elverum, Norway
Int Orthop 35:903-7. 2011.... - Cardiorespiratory and vascular dysfunction related to major reconstructive orthopedic surgeryO E Dahl
Department of Orthopaedics, Ullevaal University Hospital, Oslo, Norway
Acta Orthop Scand 68:607-14. 1997..All these effects may finally induce hemodynamic insufficiency, which occasionally may be fatal. To prevent these adverse reactions, thrombin activity should be reduced and impaction of bone cement minimized... - A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacementBengt I Eriksson
Department of Orthopaedics, Sahlgrenska University Hospital Ostra, SE 416 85 Gothenburg, Sweden
Circulation 114:2374-81. 2006..Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--could be an alternative to heparins and warfarin for the prevention and treatment of thromboembolic disorders... - Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacementBengt I Eriksson
Orthopaedics Department, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
Thromb Haemost 89:288-96. 2003..0%) and 306/1122 (27.3%) patients in the ximelagatran and enoxaparin group, respectively, a difference in risk of 3.7% in favour of enoxaparin (p = 0.053). Bleeding was comparable between the two groups... - Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment toolMeyer Michel Samama
Service d Hematologie Biologique, Hopital Hotel Dieu, 1, place Parvis Notre Dame, F 75181 Paris, Cedex 04, France
Haematologica 88:1410-21. 2003..As the first step in creating a tool to assess an individual patient's risk of venous thromboembolism, we carried out a literature review in order to quantify risk factors for venous thromboembolism... - Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitorsBengt I Eriksson
Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
Drugs 64:577-95. 2004..Ximelagatran can be used with an oral fixed dose without the need for coagulation monitoring or dose adjustment. Hence, it offers significant potential to facilitate the management of anticoagulation in or out of hospital... - An electronic tool for venous thromboembolism prevention in medical and surgical patientsMeyer Michel Samama
Hotel Dieu, Paris, France
Haematologica 91:64-70. 2006..Because appropriate prevention with thromboprophylaxis is underused, we wanted to create an electronic tool to provide a simple risk assessment and suggest appropriate prophylaxis... - Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studiesWilliam D Fisher
McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada
Thromb Haemost 97:931-7. 2007..Overall, rivaroxaban total daily doses of 5-20 mg had the most favorable balance of efficacy and safety, relative to enoxaparin, for the prevention of VTE after major orthopaedic surgery... - Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trialBengt I Eriksson
Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
Lancet 360:1441-7. 2002..We aimed to compare the efficacy and safety with that of dalteparin... - Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacementWolfgang Mueck
Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
Thromb Haemost 100:453-61. 2008.... - Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgeryWolfgang Mueck
Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
Clin Pharmacokinet 47:203-16. 2008.... - Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacementBengt I Eriksson
Department of Orthopaedics, Sahlgrenska University Hospital Ostra, SU Ostra sjukhuset, SE 41685 Goteborg, Sweden
Thromb Res 120:685-93. 2007..Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in clinical development for the prevention of thromboembolic disorders. The aim of this study was to demonstrate proof-of-principle for rivaroxaban...